Use of rapamycin slows progression of cardiac transplantation vasculopathy

Circulation

Volumn 108, Issue 1, 2003, Pages 48-53

  Mancini, Donna ^a   Pinney, Sean ^a   Burkhoff, Daniel ^a   LaManca, John ^a   Itescu, Silviu ^a   Burke, Elizabeth ^a   Edwards, Niloo ^a   Oz, Mehmet ^a   Marks, Andrew R ^a  

^a NONE

Author keywords

Atherosclerosis; Drugs; Transplantation; Vasculature

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; AZATHIOPRINE; CALCIUM CHANNEL BLOCKING AGENT; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HLA ANTIBODY; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS;

ADULT; AGED; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ARTHRALGIA; ARTICLE; ATHEROSCLEROSIS; BACTERIAL PNEUMONIA; BRONCHITIS; CELL ASSAY; CELLULITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; DEATH; DEMOGRAPHY; DIABETES MELLITUS; DISEASE COURSE; DISEASE SEVERITY; DIVERTICULITIS; DRUG ACTIVITY; DRUG EFFECT; DRUG UTILIZATION; ENDOCARDIAL BIOPSY; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GRAFT REJECTION; HEART CATHETERIZATION; HEART GRAFT; HEART INFARCTION; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY FAILURE; LEG EDEMA; LYMPHOCYTE PROLIFERATION; LYMPHOPROLIFERATIVE DISEASE; MALE; OPEN STUDY; PATIENT MONITORING; PERIPHERAL EDEMA; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SEPSIS; SIDE EFFECT; SOLID TUMOR; STATISTICAL ANALYSIS; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME; URINARY TRACT INFECTION; VASCULAR DISEASE;

ARTERIAL OCCLUSIVE DISEASES; AUTOANTIBODIES; COHORT STUDIES; CORONARY ARTERIOSCLEROSIS; CYCLOSPORINE; DISEASE PROGRESSION; FEMALE; GRAFT REJECTION; HEART CATHETERIZATION; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFECTION; KIDNEY FAILURE; MALE; MIDDLE AGED; NEOPLASMS; PROSPECTIVE STUDIES; SIROLIMUS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0038300674     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000070421.38604.2B     Document Type: Article

References (34)

1. Julius BK, Attenhofer JCH, Sutsch G, et al. Incidence, progression and functional significance of cardiac allograft vasculopathy after heart transplantation. Transplantation. 2000;69:847-854.
2. Constanzo M, Naftel D, Pritzker M, et al. Heart transplant coronary artery disease detected by coronary angiography: a multi-institutional study of preoperative donor and recipient risk factors. J Heart Lung Transplant. 1998;17:744-753.
3. Gould DS, Auchincloss HJ. Direct and indirect recognition: the role of MHC antigens in graft rejection. Immunol Today. 1999;20:77-82.
4. Avery RK. Viral triggers of cardiac allograft dysfunction. N Engl J Med. 2001;344:1545-1547.
5. Young J. Allograft vasculopathy. Circulation. 1999;100:458-460.
6. Marx S, Jayaraman T, Go L, et al. Rapamycin-FKBP inhibits phosphorylation of retinoblastoma protein and blocks vascular smooth muscle cell proliferation Circ Res. 1995;76:412-417.
7. Poon M, Marx SO, Gallo R, et al. Rapamycin inhibits vascular smooth muscle cell migration J. Clin Invest. 1996;98:2277-2283.
8. Sehgal S. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem. 1998;31:335-340.
9. Poston R, Bilingham M, Hoyt E, et al. Rapamycin reverses chronic vascular disease in a novel cardiac allograft model. Circulation. 1999;100:67-74.
10. Gallo R, Padurean A, Jayaraman T, et al. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation. 1999;99:2164-2170.
11. Sousa J, Costa M, Abizaid A, et al. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human arteries. Circulation. 2001;103:192-194.
12. kip1. Mol Cell Biol. 1996;16:6744-6751.
13. Marx S, Marks A. Bench to bedside: the development of rapamycin and its application to stent restenosis. Circulation. 2001;104:852-855.
14. Kahan B, Podbielski J, Napoli K, et al. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation. Transplantation. 1998;66:1040-1046.
15. Groth C, Backman L, Morales J, et al. Sirolimus (rapamycin) based therapy in human renal transplantation. Transplantation. 1999;67:1036-1042.
16. Deleted in proof.
17. McGiffin D, Savunen T, Kirklin J, et al. Cardiac transplant coronary artery disease. J Thorac Cardiovasc Surg. 1995;109:1081-1089.
18. Billingham M, Cary N, Hammond E, et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: heart rejection study group. J Heart Lung Transplant. 1990;9:587-593.
19. Itescu S, Tung T, Burke E, et al. An immunological algorithm to predict risk of high grade rejection in cardiac transplant recipients. Lancet. 1998;352:263-270.
20. Fischer PE, Suciu-Foca N, Ho E, et al. Additive value of immunologic monitoring to histologic grading of heart allograft biopsy specimens: implications for therapy. J Heart Lung Transplant. 1995;14:1156-1161.
21. Mehra M, Ventura H, Smart F, et al. An intravascular ultrasound study of the influence of angiotensin converting enzyme inhibitors and calcium entry blockers on the development of cardiac allograft vasculopathy. Am J Cardiol. 1995;75:853-854.
22. Launch R, Ballester M, Marti V, et al. Efficacy of augmented immunosuppressive therapy for early vasculopathy in heart transplantation. J Am Coll Cardiol. 1998;32:413-419.
23. Schroeder J, Gao S, Alderman E, et al. A preliminary study of diltiazem in the prevention of coronary artery disease in heart transplant recipients. N Engl J Med. 1993;328:164-170.
24. Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med. 1995;333:621-627.
25. Wenke K, Meiser B, Thiery J, et al. Simvastatin reduces graft vessel disease and mortality after heart transplantation: a 4 year randomized trial. Circulation. 1997;96:1398-1402.
26. Liu Z, Sun YK, Xi YP, et al. Contribution of direct and indirect recognition pathway to T cell alloreactivity. J Exp Med. 1993;177:1643-1650.
27. Liu Z, Colovai AI, Tugulea S, et al. Indirect recognition of donor HLA-DR peptides in organ allograft rejection. J Clin Invest. 1996;98:1150-1157.
28. Tugulea S, Ciubotariu R, Colovai AI, et al. New strategies for early diagnosis of heart allograft rejection. Transplantation. 1997;64:842-847.
29. Vanderlugt CJ, Miller SD. Epitope spreading. Curr Opin Immunol. 1996;8:831-836.
30. Rose EA, Pepino P, Barr M, et al. Relation of HLA antibodies and graft atherosclerosis in human cardiac allograft recipients. J Heart Lung Transplant. 1992;3:S120-S123.
31. Mamula MJ, Janeway CA Jr. Do B cells drive the diversification of immune responses? Immunol Today 1993;14:151-154.
32. Reed EF, Hong B, Ho E, et al. Monitoring of soluble HLA alloantigens and anti-HLA antibodies identifies heart allograft recipients at risk of transplant associated coronary artery disease. Transplantation. 1996;61:556-572.
33. Kapadia SR, Nissen SE, Ziada KM, et al. Development of transplant vasculopathy and progression of donor transplant atherosclerosis: a comparison by serial intravascular ultrasound imaging. Circulation. 1998;98:2672-2678.
34. Keogh A, Valantine H, Hunt S, et al. Impact of proximal or mid-vessel discrete coronary artery stenoses on survival after heart transplantation. J Heart Lung Transplant. 1992;11:892-901.